Clinical Relevance of Dissolution Testing in Quality by Design by Dickinson, Paul A. et al.
Mini-Review
Themed Issue: Bioequivalence, Biopharmaceutics Classification System, and Beyond
Guest Editors: James E. Polli, Bertil S. Abrahamsson, and Lawrence X. Yu
Clinical Relevance of Dissolution Testing in Quality by Design
Paul A. Dickinson,
2 Wang Wang Lee,
1,6 Paul W. Stott,
2 Andy I. Townsend,
2 John P. Smart,
2 Parviz Ghahramani,
3
Tracey Hammett,
3 Linda Billett,
4 Sheena Behn,
5 Ryan C. Gibb,
2 and Bertil Abrahamsson
2
Received 13 March 2008; accepted 31 March 2008; published online 7 August 2008
Abstract. Quality by design (QbD) has recently been introduced in pharmaceutical product development
in a regulatory context and the process of implementing such concepts in the drug approval process is
presently on-going. This has the potential to allow for a more flexible regulatory approach based on
understanding and optimisation of how design of a product and its manufacturing process may affect
product quality. Thus, adding restrictions to manufacturing beyond what can be motivated by clinical
quality brings no benefits but only additional costs. This leads to a challenge for biopharmaceutical
scientists to link clinical product performance to critical manufacturing attributes. In vitro dissolution
t e s t i n gi sc l e a r l yak e yt o o lf o rt h i sp u r p o s ea n d the present bioequivalence guidelines and
biopharmaceutical classification system (BCS) provides a platform for regulatory applications of in vitro
dissolution as a marker for consistency in clinical outcomes. However, the application of these concepts
might need to be further developed in the context of QbD to take advantage of the higher level of
understanding that is implied and displayed in regulatory documentation utilising QbD concepts. Aspects
that should be considered include identification of rate limiting steps in the absorption process that can
be linked to pharmacokinetic variables and used for prediction of bioavailability variables, in vivo
relevance of in vitro dissolution test conditions and performance/interpretation of specific bioavailability
studies on critical formulation/process variables. This article will give some examples and suggestions
how clinical relevance of dissolution testing can be achieved in the context of QbD derived from a
specific case study for a BCS II compound.
KEY WORDS: bioequivalence; biopharmaceutics classification system (BCS); biowaiver; in vitro
dissolution; in vitro in vivo correlation (IVIVC); quality by design (QbD).
INTRODUCTION
The regulatory framework surrounding the manufacture
of pharmaceutical products ensures patient safety through the
use of well-defined processes with specified parameter ranges
governed by a change control process, which places a
significant burden on industry. As a consequence, it is difficult
to implement a continuous improvement culture and some
manufacturing processes remain fixed and suboptimal to the
detriment of industry, the payer and potentially the patient.
However, under the new Quality by Design paradigm (QbD)
(1) it will be possible to use knowledge and data from product
development studies to create a design space within which
continuous improvement can be implemented but where the
burden for management of change control lies within Industry
without the need to seek further regulatory approval. This
represents a fundamental shift in the relationship between
regulators and the pharmaceutical scientists and will have a
major impact on the way pharmaceutical products and
processes are developed and their quality assured.
Traditionally pharmaceutical development has focused
on the delivery of product to the next phase of clinical studies
and thus formulation design has tended to be iterative and
empirical. Change was driven by the need to modify process
as part of scale up or where an early clinical formulation did
not posses the required attributes for a commercial product
(e.g. shelf-life). Where possible, change during phase III was
kept to a minimum to avoid the need for bioequivalence
studies (in vitro or in vivo) to bridge between pivotal clinical
trial material and commercial product. Manufacturing pro-
cesses were therefore fixed early with the intention that
material produced from those processes would be equivalent
in quality and that quality was measured by end product
testing to specification. Dissolution testing was then used to
demonstrate that batches of product have similar perfor-
mance to pivotal clinical batches. Generally, there is no
1550-7416/08/0200-0280/0 # 2008 American Association of Pharmaceutical Scientists 280
The AAPS Journal, Vol. 10, No. 2, June 2008 (# 2008)
DOI: 10.1208/s12248-008-9034-7
1UG22, Lab Block, Pharmaceutical & Analytical R&D, AstraZeneca,
Macclesfield, Cheshire SK10 2NA, England.
2Pharmaceutical & Analytical R&D, AstraZeneca, Macclesfield,
Cheshire SK10 2NA, England.
3 Clinical Development, AstraZeneca, Macclesfield, Cheshire,
England.
4Regulatory Affairs, AstraZeneca, Macclesfield, Cheshire, England.
5Operations, AstraZeneca, Macclesfield, Cheshire, England.
6To whom correspondence should be addressed. (e-mail: WangWang.
Lee@astrazeneca.com)relationship established between the in vitro test and in vivo
performance for immediate release solid dosage forms.
This approach often leads to the desired clinical attrib-
utes provided by the formulation not being considered
explicitly at the onset of development and consequently not
designed into the product. In this environment, testing of the
product was performed post manufacture to ensured quality
of clinical or commercial batch. While this approach has been
successful in assuring product quality to the public, it has led
to a less efficient pharmaceutical development manufacturing
sector. This impacts on the availability and costs of medicines
to society (2) and it does not build the understanding that
facilitates continuous improvements. In recognition of this,
significant opportunities are available currently to improve
pharmaceutical development and manufacturing via a shift in
approaches to product and process development, analysis,
control and regulation. As pharmaceuticals continue to have
an increasingly prominent role in healthcare, Quality by
Design (QbD) has recently been introduced in pharmaceuti-
cal product development in a regulatory context (1).
The aim of QbD is to make more effective use of the
latest pharmaceutical science and engineering principles and
knowledge throughout the lifecycle of a product. This has the
potential to allow for more flexible regulatory approaches
where, for example, post-approval changes can be introduced
without prior approval and end-product batch testing can be
replaced by real time release. Through this understanding,
the process and product can be designed to ensure quality
and the role of end product testing is reduced. Under QbD,
dissolution becomes a key tool for understanding product
performance and for measuring the impact of changes in
input parameters or process. A design space bounded by
clinical quality rather than equivalent dissolution may allow
greater opportunity for continuous improvement without
regulatory approval. (Clinical quality is defined as the
product having attributes that assure the same safety and
efficacy as the pivotal clinical trial. For the purpose of this
paper, the product will be bioequivalent or have equivalent
pharmacokinetics as the pivotal trials product.)
In this context good pharmaceutical quality ensures that
the risk of not achieving the desired clinical attributes is
acceptably low (3). The pharmaceutical industry has taken
steps to embrace QbD via the development of a discussion
document known as ‘Mock P.2’ with a fictitious tablet
product, Examplain (4,5).
Establishing boundaries based on the clinical impact of
the product design and manufacturing process is a challenge
for biopharmaceutical scientists, as links needs to be estab-
lished from manufacturing and composition variables to
product clinical performance. The different components of
this chain of events related to safety/efficacy of the active
drug is illustrated in Fig. 1.
Traditional surrogates for measuring clinical quality (i.e.
clinical pharmacokinetics studies) are not viable for the large
number of batches generated during process establishment, as it
isnotfeasibletotestallbatchesintheclinic.UnderQbD,variants
would be deliberately made at the extremes of the proposed
design space to look for variability rather than trying to make all
batches equivalent. The present bioequivalence guidelines and
biopharmaceutical classification system (BCS) provides a plat-
form for application of in vitro dissolution as a surrogate for
clinical quality. However to support QbD, the application of
dissolution needs to be further developed beyond generic
approaches to compound and product specific applications. This
can be achieved by presenting a higher level of understanding
which incorporates a link to clinical quality in regulatory
documentation and applying risk based concepts which are also
an important element in the new regulatory paradigm (6).
Therefore, the following paper will review the current
accepted practices for demonstrating clinical quality and then
propose further development of these practises to meet the
needs of pharmaceutical development, manufacture and
regulation in the twenty-first century, particularly focussing
on approaches for BCS II compounds. These approaches will
focus on the evaluation of the clinical impact of key product
and process variables leading to establishment of the clinical
boundary of the design space and subsequent potential
regulatory flexibility and continuous improvement which is
part of the FDA pilot programme (7). Finally a generic
overview of the approaches for BCS II compounds and
suggestion for BCS III and IV compounds will be presented.
This review is focussed on understanding the safety and efficacy
of a product in relation to bioavailability of the parent drug, as
drug pharmacokinetics are widely accepted as a surrogate for
safety and efficacy (8,9). Aspects of safety and efficacy related
to impurities and degradation products or other much less
common factors such as excipient interactions on pharmacoki-
netics beyond dissolution effects and local irritation caused by
API or excipients are not discussed in this paper.
BODY
Established Approaches to Assure Clinical Quality
Clinical quality in a QbD context should ideally be
defined for a certain compound based on a relationship
between pharmacokinetics (PK) and pharmacodynamics
(PD) of desirable and undesirable effects. However, due to
the difficulty of establishing such PK/PD relationships and the
need for validation of PD biomarkers to clinical efficacy and
safety this information is not readily available in many
development projects. In such cases, the pharmacokinetic
limits defined in the regulatory framework within the
bioequivalence area provides a conservative basis to define
clinical quality. Translated to the QbD situation this implies
Fig. 1. Different steps to be considered in relating manufacturing
variables to clinical
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composition changes should produce products with in vivo
performance within acceptance criteria for bioequivalence.
Development of other more novel approaches to establish
clinically meaningful quality criteria should be an area for
future research and consideration but is outside the scope for
the present paper. Also, it is the intention here to present the
process to link in vitro methods to clinical outcomes rather
than a discussion on formulation and process parameters that
should be investigated.
Currently, the general approach in US and Europe for
demonstrating equivalent safety and efficacy for a new or
changed product relative to the approved or early phase clinical
trial product is shown in Fig. 2. In summary clinical quality
(safety and efficacy) can be assessed by comparing drug
pharmacokinetics in volunteers after administration of the
reference and new product (Bioequivalence studies) or for
BCS Class I compounds comparing dissolution across the
physiological pH range (8–10). The BCS is used to describe the
key factors for predicting drug absorption in man and identify
the likelihood that changes to the formulation or manufactur-
ing process will affect clinical pharmacokinetics and therefore
safety and efficacy (10). Thus according to BCS, a substance is
categorised on the basis of its aqueous solubility (sol) and
intestinal permeability (perm) where four classes are defined
[Class I (high sol/high perm), II (low sol/high perm), III (high
sol/low perm), and IV (low sol/low perm)]. Additionally, the
properties of drug substance are combined with the dissolution
characteristics of the drug product to control clinical quality.
The drugs with high solubility and high permeability are
g r o u p e da sC l a s sId r u g sf o rw h i c hb i o w a i v e r sa r ep o s s i b l e
(8,9). For the remaining classes, a bioequivalence study is
generally required because in vitro tests that could be used to
assess the impact of the changes on clinical safety and efficacy
are not readily available. However some (smaller) changes,
which have been shown to have a low probability of affecting
drug dissolution (11) and absorption, thus safety and efficacy,
can be assessed using dissolution testing (12–14). A more
comprehensive review of possibilities for replacing in vivo
bioequivalence studies with in vitro dissolution has been
published (15). Moving forward towards meaningfully large
design spaces (1) will likely require changes greater than those
allowed under SUPAC (Scale-Up and Postapproval Changes).
It is also not practical to test all potential product variants
generated during the establishment of product and manufac-
turing design space in the clinic. Therefore, using compound
specific knowledge it will be necessary to establish a link
between in vitro tests and the safety and efficacy (volunteer
PK). Once this link has been established, the in vitro
(dissolution) test can be used as a surrogate of clinical
performance and the clinical performance of all variants from
the design space establishment can be assessed. Taking the
concept of using volunteer pharmacokinetics to measure safety,
efficacy and dissolution, the following Section describes an
approach to establish a compound/product specific dissolution
test that is a surrogate for bioavailability.
Use of Dissolution Testing as a Surrogate for Clinical Quality
Assessment in QBD-Case Example
Compound Properties
The compound has a molecular weight of 475 with a ClogP
of5.7andLogD(Octanol)2.6.Thedrugsubstanceisaweakbase
with pKa 9.41 and 5.33 (dibasic) that displays high permeability
but low solubility due to low solubility above pH 6. As such, it is a
BCS Class II compound. It is stable in gastrointestinal fluid. The
highest strength is 300 mg given as tablets.
Risk Identification, Analysis and Evaluation
It is important to identify and understand the raw
materials and process variables that could impact upon
clinical safety and efficacy through effects on dissolution.
This is especially relevant for low solubility drugs, such as the
presented compound. An Initial Clinical Quality Risk As-
sessment (6) was performed to identify these risks with an
aim to assess the in vivo impact through dissolution of the
most relevant raw material attributes and process variables.
The key question asked during this risk assessment
process was ‘what is the overall risk of each potential failure
mode affecting in vivo pharmacokinetics (and therefore
patient safety and efficacy)?’ The potential failure modes
identified as part of this process and the associated RPNs
(Risk Product Number), which represent the overall magni-
tude of risk derived from science and prior knowledge, are
Fig. 2. Evidenced required to demonstrate clinical quality according to
BCS class of compound
282 Dickinson et al.presented in Fig. 3 The RPN is a product of objective scores
taking into account detectability, probability and severity.
Figure 3 shows the failure modes with the potential to
retard dissolution rate, for example, drug substance particle
size, has the highest risk of impacting in vivo pharmacokinet-
ics. The highest risks to the clinical performance of drug
product tablets (shown in red) were identified and are
presented in Table I with their respective dissolution retar-
dation mechanisms.
The highest risk factors had been identified and covered
a broad range of potential in vivo dissolution retardation
mechanisms. The next step was to manufacture a range of
tablets incorporating these variables that could be tested in a
clinical study to assess the impact of varying these variables
on in vivo pharmacokinetics. Due to ethical and logistical
reasons testing of all potential variables in vivo was imprac-
tical. Therefore, the bioavailability of tablet variants manu-
factured to incorporate relevant retardation mechanisms
through changes of only the highest risk raw materials and
process variables was assessed in a volunteer study. Future
variants (which should be lower risk than those tested in vivo)
would then be assessed using a discriminatory in vitro
validated dissolution test that would be developed to act as
a surrogate for in vivo data. Another advantage of this
approach is that it may allow the development of an in vitro in
vivo correlation (IVIVC).
Based on the output from the Initial Clinical Quality
Risk Assessment, four tablet variants were developed incor-
porating the highest risk product and process variables
(Table II). All of these tablets were based on the commercial
Fig. 3. Initial risk assessment of product and process variables that could affect clinical quality through dissolution
Table I. Highest Risk Failure Modes with the Potential to Impact In Vivo Pharmacokinetics
Failure mode  Dissolution retardation mechanism 
Changes in drug substance particle size  Impact of drug substance surface area on rate of 
dissolution (particle size was varied as easiest to 
control and characterise, also changes in 
particle size are likely to have a larger impact than 
other properties, as the drug substance quality is 
fixed) 
Failure to control granulation end-point; 
over-granulation
Impact of granule density and porosity on the rate of 
ingress of water 
Increased level of binder in the formulation 
Decreased level of disintegrant in the 
formulation 
Impact of slowed tablet disintegration rate on 
subsequent drug dissolution 
283 Clinical Relevance of Dissolution Testing in Quality by Designtablet formulation, which is represented as the standard tablet
(Variant A). The variants consisted of a drug substance particle
size variant, a process variant and a formulation variant.
All three tablet variants, plus the standard tablet, were
tested using a preliminary discriminatory dissolution test (see
below). This assessment ensured that tablets were included
that covered both a range of dissolution profiles and all the
dissolution retardation mechanisms previously identified. This
provided the greatest chance of establishing an IVIVC and
ensuring the broad applicability of the selected dissolution test.
Establishment of Dissolution Method Conditions
Initially, consideration was given to the standard
approaches to the development of a dissolution method such
as that proposed by the FDA (16). Following this approach,
pH modification alone would have produced a method, which
allowed complete release (pH 1.2, USP2, 50 rpm) and also
had some physiological relevance (that is conditions repre-
sentative of the stomach).
However, this would have been incompatible with the
scientific risk-based approach in which the risk assessment
and risk evaluation steps of the overall risk assessment stage
(6) are fundamental to understanding the risk control strategy
to be adopted. Within this framework the following elements
were considered particularly important:
1. Identification of hazard
2. Likelihood of hazard occurring
3. Impact of hazard occurring
4. Ability to detect event.
Within this context and by consideration of ICH Q6A
guidance (17), the objectives for the initial dissolution method
was:
1. To distinguish amongst different processing and
formulation variables
2. To have in vivo relevance
3. To complete dissolution within a timescale appropri-
ate for a routine control test (this is a desirable feature
Table II. Tablet Variants Incorporating Highest Risk Product and Process Variables
Tablet variant Description Variant
A Standard tablet NA
B Drug substance particle size variant Increased particle size
C Processing variant Increased water quantity and granulation time
D Formulation variant Increased binder and decreased disintegrant level
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Fig. 4. Mean (n=6) tablet dissolution in various media. a pH 1.2 b pH 4.5 c pH 6.8 d water with surfactant providing solubilisation
284 Dickinson et al.but sometimes separate in vivo predictive in vitro
methods may be needed which is not suitable for
routine control)
The dissolution of the tablets was assessed in aqueous
buffers across the pH range 1.2 to 6.8 (see Fig. 4). At low pH,
tablet dissolution was fast with high variability observed
between individual tablets and poor discrimination. At
neutral pH, low recoveries were observed due the low
solubility of the drug at pH 6.8. From these studies, it was
concluded that aqueous buffers did not provide the optimum
conditions for a test capable of differentiation between
processing and formulation variables for the tablets.
In accordance with Dissolution testing guidance for
industry (18), the use of surfactants to increase solubility by
micellar solubilisation was evaluated. The dissolution of
tablets was assessed in surfactant containing media. Dissolu-
tion in one surfactant media exhibited the potential for
differentiation between processing and formulation variables
while providing conditions resembling to the small intestine
where bile acid mixed micelles acts as solubilisers (Fig. 4). The
optimum surfactant concentration was identified and at this
concentration, the rate of tablet dissolution was sufficiently
slow to provide the potential for discrimination between tablet
variants whilst affording complete dissolution within a time-
scale appropriate for use as a routine control test.
The in vitro performance (dissolution rate) of the three
tablet variants, plus the standard tablet, was assessed using
the preferred method, the dissolution test with surfactant.
The dissolution profiles obtained demonstrated differentia-
tion between the tablet variants, indicating that the method
can detect changes in the drug product caused by deliberately
varying the highest risk process parameters and product
attributes identified from the Initial Clinical Quality Risk
Assessment.
Evaluation of the Tablet Variants In Vivo
Once these tablet variants had been produced incorpo-
rating the highest risk product and process variables identi-
fied from the Initial Primary Quality Risk Assessment and
providing a good range of in vitro dissolution profiles, they
were dosed in a clinical volunteer pharmacokinetic study,
together with an oral solution. The solution was to be used as
a comparison to the tablet variants both as a reference to
allow calculation of in vivo dissolution of the tablets via
deconvolution and also to demonstrate whether more rapid
dissolution than Variant A (standard tablet) would still
produce the same clinical safety and efficacy. The wide
dissolution range allowed the best opportunity for an IVIVC
to be developed. This could be achieved in accordance with
the IVIVC guidance for Industry (14). This guidance is
relevant, as the concepts it contains are applicable to the
development of an IVIVC for a BCS Class II compound in an
immediate release product when dissolution is the rate-
determining step.
Fig. 5. Geometric mean and individual plasma drug concentrations from tablet variants (n=10 for tablets a and b, n=11 for tablet c and n=9
for tablet d) versus an oral solution (n=15) after dosing to healthy volunteers
285 Clinical Relevance of Dissolution Testing in Quality by DesignThe plasma concentration-time profiles for the oral
solution and each of the 4 drug substance tablet variants are
summarized in Fig. 5.
The 4 tablet variants exhibited similar in vivo performance
and thus it was concluded that the clinical pharmacokinetics of
the drug were not affected significantly by the variations in the
tablets assessed in this study. As the 4 tablet variants have
similar in vivo performance but different in vitro profiles it was
apparent that there would be no direct relationship and so
development of an IVIVC was not attempted.
In summary, the in vitro dissolution test was able to
differentiate between the tablet variants incorporating the
highest risk product and process variables resulting in slower
in vitro dissolution. However, the slower in vitro dissolution
had no significant impact on the pharmacokinetics of drug
substance in human subjects. This lack of dependency could
be explained by a high enough drug solubility in the GI tract
which means that dissolution is faster than other physiological
processes (e.g. gastric emptying and permeation). Also the
long elimination half-life makes Cmax less sensitive to changes
in absorption rate. The in vivo study demonstrated that:
1. The product and process variables and related retar-
dation mechanisms investigated in this study do not
impact on clinical pharmacokinetics within tested
ranges
2. Tablets manufactured with a dissolution rate greater
than or equal to that of the slowest dissolving
formulation (Tablet Variant D) will demonstrate
equivalent pharmacokinetics to the standard tablets
(Tablet Variant A) and to an oral solution.
& That dissolution rate is not important within the
range studied
& Tablet variants with dissolution profiles more rapid
than that of Tablet Variant A will also produce
similar bioavailability as evidenced by the similar
performance of the oral solution.
3. As the variants dosed encompassed three different
mechanisms to alter drug release from the tablet the
overly discriminatory dissolution test is a sensitive
surrogate to assess clinical quality of all outputs from
further processing studies.
Application of Clinically Relevant Dissolution Criteria
in Establishment of a Design Space
QbD principles have been utilised to develop the
product and gain an in-depth understanding of the clinical
impact of the highest risk product and process variables.
Initially, these risks were considered to be relatively high
based on unknown probability (default high score), high
severity and low detectability (high risk score). However,
after execution of a successful risk reduction programme,
which included the manufacture of tablet variants incorpo-
rating the highest risk variables, the development of a
clinically relevant dissolution test, and the dosing of the
tablet variants in the in vivo study, it was clear that the
absolute risk was low. This is based on the fact that
probability is now considered low for the highest risks, with
detectability increased, and severity reduced. If future
product is shown to have a dissolution profile faster than
Variant D, clinical quality will be assured. These concepts
were used to establish the design space (1) for the product.
Furthermore the dissolution test will assist in the
qualification of future changes such as site, scale, equipment,
and method of manufacture using the dissolution method and
limit provided by Variant D.
Use of Dissolution Testing as a Surrogate for Clinical Quality
Assessment in QbD-Recommendations
From examination of the case study five key steps to
ascertaining clinical performance by dissolution testing in
QbD can be identified. These are:
1. Conduct Quality Risk Assessment (QRA) to allow
the most relevant risk to clinical quality to be
identified based on prior knowledge of this and other
products.
2. Develop dissolution test(s) with physiological rele-
vance that is most likely to identify changes in the
relevant mechanisms for altering drug dissolution,
e.g. testing at lowest acceptable solubility/mildest
agitation.
3. Understand the importance of changes to these most
relevant manufacturing variables on clinical quality
based on dissolution data combined with
a. BCS based prior knowledge
b. And/or clinical ‘bioavailability’ data
4. Establish the dissolution limit which assure clinical
quality (i.e. no effect by changes)
a. Clinical ‘bioavailability/exposure’ data
i. Classical IVIVC (already accepted today in
SUPAC)
ii. In vivo “safe space” (see below)
b. Prior knowledge (BCS).
5. Ensure dissolution within established limits to assure
clinical quality used to define a Design Space.
The above example illustrates the approach to be used
for a class II drug in connecting dissolution to bioavailability
and thereby assuring clinical quality of a product. A BCS
based approach on how to establish the link for drugs
according to class I, III and IV are proposed in Fig. 6.
For Class I drugs, it is proposed that dissolution within
30 min would provide sufficient assurance of clinical quality.
This limit is based on the present understanding that for such
a rapid dissolution, product drug dissolution does not affect
rate and extent of absorption for a class I drug (10). For BCS
class I drugs in vitro dissolution is already accepted as
surrogate for in vivo studies for IR formulations with
sufficiently rapid dissolution (8,10) and should thus be
possible to apply also within the context of QbD. Thus, no
specific IVIVC studies would be needed to establish a
clinically relevant Design Space. The current regulatory
guidance suggests testing at three different pH within the
physiological range and the use of mild agitation (100 rpm in
USP I method or 50 rpm in USP II method). In context of
QbD, testing at most challenging pH with respect to drug
solubility would be sufficient unless the risk analysis identifies
other pH dependent effects on dissolution such as pH
dependence of critical excipients.
286 Dickinson et al.This simpler approach should also be possible to apply to
class III drugs. The suitability of dissolution as a surrogate for
bioequivalence studies of class III drugs is generally not
accepted in context of formulation changes or generic
products. However, it should be noted that in context of
QbD, a more “knowledge rich” situation where risks are
identified, carefully evaluated and mitigated provides more
favourable conditions for replacing in vivo studies with in
vitro tests. In addition, it has been proposed to extend the use
of biowaivers based on dissolution testing to class III drugs
(19–22). The scientific rationale being that for products with
rapid dissolution, this is not a rate limiting factor in the
absorption process and thereby a low risk factor. This has
been illustrated in simulations by Kortejarvi and colleagues
which showed that the difference in Cmax was less than 10%
for a solid dosage form with complete dissolution after 1 hour
and a solution for a wide range of elimination rates and low
permeabilities (23). This insensitivity has also been confirmed
by in vivo studies with metformin (22) and ranitidine (24).
Thus, applying dissolution testing as a surrogate for bioavail-
ability studies in context of QbD represents an acceptably low
risk provided that excipients that could affect permeability or
gastro-intestinal transit are not changed. Similar in vitro
testing strategies as described for class I drugs above, i.e.
testing at most discriminating conditions, is judged to be
sufficient also for class III drugs. Although simulations show
that absorption of class III drugs are less sensitive to
dissolution variations within normal limits than class I drugs
(23) the impact of substantially delayed dissolution in vivo is
potentially higher for class III drug due to risk of a reduction
in extent of absorption if dissolution occurs in more distal
parts of the gastro-intestinal tract. As a result, a more
conservative dissolution limit of 15 min is proposed for class
III drugs. If slower product dissolution than the above
proposed limits is desired for class I and III drugs, a
bioavailability study is probably needed using the same
approach suggested for class II drugs.
The same approach as suggested for class II drugs should
also be applicable to class IV drugs provided that are no
additional effects beyond dissolution that could affect bio-
availability like excipient changes affecting permeability are
considered. It should be noted that the BCS classification is a
Fig. 7. The role of drug BCS class in defining the approach to setting
dissolution specifications
Fig. 6. The role of BCS in defining the approach to ascertaining
clinical performance by dissolution testing within QbD
287 Clinical Relevance of Dissolution Testing in Quality by Designfairly conservative approach where drugs classified as having
low solubility actually could behave as a high solubility drug,
e.g. shown by similar plasma profile for solution and solid
formulation. In such a case, class IV drugs could be handled
similar to class III drugs.
Setting Specifications within QbD
A generic approach to the establishment of a dissolution
test that controls clinical quality and the role of BCS within this
has been described. The final aspect to this approach is to set a
dissolution specification that assures safety and efficacy (Fig. 7).
For a BCS Class II compound, as the case example
above, 3 scenarios exist as illustrated in Fig. 8, these are:
1. A classical level A IVIVC (14) is established and a
specification that controls Cmax and AUC by maxi-
mum ±10% is set in accordance with available
acceptance criteria.
2. A “safe space” specification is set based on no effect
seen in the clinical study and the slowest dissolution
profile tested in the clinical study (i.e. what occurred
in the case study presented—in this case the specifi-
cation is set at the boundary of knowledge rather than
on a biological effect).
3. The final option is a mixed safe space/IVIVC result in
which clinical pharmacokinetics is only affected for a
few of the variants tested clinically. Again this would
allow a dissolution specification to be set that allowed
Cmax and AUC to be controlled to 10%.
Further Investigation of Safe Space Concept by Absorption
Simulations
Generally, it is believed that IVIVC is possible for Class
II if in vitro dissolution rate is similar to in vivo dissolution
rate (10). However, the above case example illustrated a
situation where a classical IVIVC was not achieved, not due
to a failure of the in vitro dissolution method but as a
consequence that dissolution was not a critical factor for peak
plasma levels and extent of exposure within the range
studied. Modelling by use of absorption simulation software
was performed to further explore the likelihood of attaining
such “safe space” for class II drugs by probing the role of
physiological factors like gastric emptying and permeation
rate in relation to the dissolution rate.
In vitro and in vivo simulations were conducted. Disso-
lution profiles were generated in silico using the Noyes-
Whitney/Nernst-Brunner expression based on solubility and
other physicochemical inputs. Particle size was varied to
mimic different formulation performance (25,26). Disposition
pharmacokinetics was described by a compartmental phar-
macokinetic model. Plasma profiles were simulated for a
neutral compound with poor solubility (0.02μg/ml, chosen to
represent a Class II compound at 30 mg), and with high or
very high permeability (Peff 10 and 40×10
−4 cm/s). A
suspension where particle size was varied to change the
dissolution rate and a solution (‘infinite’ solubility) were also
modelled. Two gastric emptying rates were studied with both
formulation types: fast (0.1 min) and average (15 min). It was
shown that only when gastric emptying rate was fast and
permeability very high that a level A IVIVC across the
dissolution range could be established. In the more
physiological relevant simulations, gastric emptying and/or
permeability had a dampening effect on absorption such that
dissolution is not rate determining and so a ‘safe space’ was
produced for faster dissolving formulations. We conclude
from this that for the magnitude of dissolution perturbations
that could be expected to be introduced into formulations by
competent formulators, ‘safe space’ or ‘mixed safe space/
IVIVC’ is the most likely outcome. This conclusion is
somewhat at variance with the perceived knowledge and
should be the subject of further research.
Polli and co-workers have performed some investigations
on this subject and developed a model to show that
immediate release products may not be expected to yield
Level A correlations (27). Instead, the degree of correlation
has been found to be in a gradual and continuous fashion
dependent on the relative rate of first-order permeation and
first-order dissolution constants (α) and the fraction of dose
absorbed. Polli and Ginski went on to investigate the model
using three compounds, metoprolol, piroxicam and ranitidine
(Class I, II and III compounds respectively). Data generated
showed that large α values (α≥1) were dissolution rate
limited, small α values (α≤1) were permeation rate limited
and when α≈1, it was ‘mixed’ dissolution rate limited and
permeation rate limited absorption (28). The modelling
described in this article is consistent with the earlier findings
of Polli and co-workers (27). It was noticed that although
Piroxicam is a BCS Class II compound and has high
permeation rate, the resulting α values for the more rapidly
dissolving formulations of piroxicam were below 1 or about 1
emphasising the possibility of a ‘safe space’ or lack of classical
Level A IVIVC for a class II compound.
In summary, a large α is required for IVIVC of a class II
compound. However, for many Class II compounds in
formulations developed by competent formulators following
Quality by Design approaches this is unlikely. The likelihood
instead is to achieve a safe space operating model, as the
quality should be higher and as consequence dissolution
sufficiently fast to produce a low α. Nevertheless, the
formulator is provided with the unique opportunity to
elucidate the mechanisms controlling oral absorption from
this class of compounds through the formulation approaches.
In the cases (mainly BCS class II and IV drugs) that
merits a specific bioavailability study to settle the link
between dissolution testing and clinical quality it is highly
Fig. 8. Changes in Cmax and AUC for Safe Space and IVIVC
establishment
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factors studied. That could be achieved by understanding the
mechanism behind the effect on drug dissolution. If this is
known, it should be possible to predict the in vivo perfor-
mance from in vitro dissolution data for all formulation/
manufacturing factors affecting the same mechanisms just by
including one representative and relevant factor in the in vivo
study. For example, if tablet disintegration is expected to be a
critical factor, tablets with different disintegration times
would be included in the in vivo study. However, disintegra-
tion could be affected by several factors such as tablet
compression, granule properties and binder/disintegrants. In
such a case, the aim of the in vivo study would be to validate
the in vitro method versus alterations in tablet disintegration
rather than against a specific formulation or process factor.
This should be possible to obtain by using tablets in the in
vivo study with different disintegration times obtained by
varying just one factor, e.g. compression force, rather than
testing all factors in vivo. Although this is a trivial example it
indicates how a higher level of understanding can be applied
in the context of QbD.
Future Perspectives
The application of dissolution testing as surrogate for in
vivo studies in establishing clinically relevant dissolution
criteria may be further developed beyond the proposals in
the present paper. Three key areas can be identified that
could be applied as is or after additional refinement by
research work;
1. Development of in vitro dissolution methods that
provides more in vivo realistic conditions
2. Establishment of relationship between dissolution and
bioavailability variables using mechanistic based com-
putational absorption modelling
3. Mechanistic understanding and modelling of drug
dissolution based on drug substance, excipient and
formulation properties.
Current dissolution methods are based on providing
an acceptable risk level as proven by long term experi-
ence rather than modelling the in vivo situation. More in
vivo relevant in vitro test methods would allow more flexible
approaches than described above further reducing the need
for additional in vivo studies. Some factors related to
medium composition have already been well established in
the literature for example, the lower surface tension in GI
fluids compared to dissolution buffers, intestinal surfactants
ionic compositions, GI volumes (29). However this knowl-
edge is not fully utilised in dissolution testing supporting
product development. More in vivo realistic methods
capturing dynamic changes of medium composition are
available or under development (30,31) that may play a role
in QbD in the future. Other factors still needing more
research and understanding in order to establish in vivo
relevant dissolution methods are modelling of intestinal
hydrodynamics, in vivo drug precipitation/solid state con-
versions and conditions for dissolution in the more distal
parts of the GI tract.
In addition, the use of algorithms that model the absorp-
tion process in a more mechanistic manner (32,33) than simple
IVIVC approaches would aid the establishment of drug
specific definitions of “safe space” dissolution limits (see
Fig. 8). This kind of approach would require validation of
applied in silico models using bioavailability data for the
specific drug obtained in development studies thereby poten-
tially removing the need to conduct specific IVIVC type
studies.
Mechanistic understanding of dissolution data can be
gained by generating information in dissolution experiments
additional to amount drug dissolved. This could for example
be obtained by imaging techniques, analysis of dissolved
excipients or particle analysis techniques like Focused Beam
Reflectance Measurements. The identification of dissolution
mechanisms in this manner enhances quality of risk assess-
ments and also possibility to define relevant in vitro test.
Computational algorithms integrating the relevant factors
controlling the drug dissolution from a product may also be
utilised in the future for example to optimise design spaces
and focus experimental efforts to relevant topics.
Itisimportantthatinvestmentsmadeintheareasaboveare
translated into models not only useful in a certain development
project but are more generally applicable in order to be cost-
efficient. Ultimately, this will be achieved by striving for
mechanisticmodelscapturingscientificknowledgeandvalidated
by project experiences. Thus, there is a need for additional
research as well as for ways to better capture project learning
and sharing to support achievement of a more efficient
pharmaceutical development and manufacturing process.
CONCLUSION
In vitro dissolution testing together with BCS consider-
ations could provide a key link between manufacturing/
product design variables and clinical safety/efficacy in QbD.
Some guides as to how to apply dissolution testing in this
context building on the current BE/BCS guidelines have been
suggested derived from a specific case study for a BCS II
compound.
The concept of IVIVC between in vitro dissolution and in
vivo drug plasma concentrations needs to be extended in
context of QbD beyond present Level A targets. “Safe space”
regions where bioavailability is unaffected by pharmaceutical
variations providing different dissolution profiles should be an
acceptable or even desirable outcome in an IVIVC type study.
Dissolution testing should be applicable to assure desired
clinical performance for a wide range of drugs supporting the
use of QbD based on BCS considerations and specific
product knowledge. This is ascertained by conducting bio-
relevant dissolution tests, assessing relevant manufacturing
variables and determining a link between dissolution and
bioavailability data as exemplified in the present paper.
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